{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:38:31Z","timestamp":1791308311192,"version":"4.3.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The clinical translation of positron emission tomography (PET) radiotracers for cancer management presents complex challenges. We have developed consensus-based recommendations for preclinical and clinical assessment of novel and established radiotracers, applied to image different cancer types, to improve the standardisation of translational methodologies and accelerate clinical implementation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A consensus process was developed using the RAND\/UCLA Appropriateness Method (RAM) to gather insights from a multidisciplinary panel of 38 key stakeholders on the appropriateness of preclinical and clinical methodologies and stakeholder engagement for PET radiotracer translation. Panellists independently completed a consensus survey of 57 questions, rating each on a 9-point Likert scale. Subsequently, panellists attended a consensus meeting to discuss survey outcomes and readjust scores independently if desired. Survey items with median scores\u2009\u2265\u20097 were considered \u2018required\/appropriate\u2019,\u2009\u2264\u20093 \u2018not required\/inappropriate\u2019, and 4\u20136 indicated \u2018uncertainty remained\u2019. Consensus was determined as\u2009~\u200970% participant agreement on whether the item was \u2018required\/appropriate\u2019 or \u2018not required\/not appropriate\u2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Consensus was achieved for 38 of 57 (67%) survey questions related to preclinical and clinical methodologies, and stakeholder engagement. For evaluating established radiotracers in new cancer types, in vitro and preclinical studies were considered unnecessary, clinical pharmacokinetic studies were considered appropriate, and clinical dosimetry and biodistribution studies were considered unnecessary, if sufficient previous data existed. There was \u2018agreement without consensus\u2019 that clinical repeatability and reproducibility studies are required while \u2018uncertainty remained\u2019 regarding the need for comparison studies. For novel radiotracers, in vitro and preclinical studies, such as dosimetry and\/or biodistribution studies and tumour histological assessment were considered appropriate, as well as comprehensive clinical validation. Conversely, preclinical reproducibility studies were considered unnecessary and \u2018uncertainties remained\u2019 regarding preclinical pharmacokinetic and repeatability evaluation. Other consensus areas included standardisation of clinical study protocols, streamlined regulatory frameworks and patient and public involvement. While a centralised UK clinical imaging research infrastructure and open access federated data repository were considered necessary, there was \u2018agreement without consensus\u2019 regarding the requirement for a centralised UK preclinical imaging infrastructure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We provide consensus-based recommendations, emphasising streamlined methodologies and regulatory frameworks, together with active stakeholder engagement, for improving PET radiotracer standardisation, reproducibility and clinical implementation in oncology.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12916-024-03831-z","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:45:56Z","timestamp":1737629156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-4651","authenticated-orcid":false,"given":"Martina A.","family":"McAteer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-5687","authenticated-orcid":false,"given":"Daniel R.","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-8134","authenticated-orcid":false,"given":"Gary J. R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-3975","authenticated-orcid":false,"given":"Hing Y.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-5619","authenticated-orcid":false,"given":"Tony","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-8497","authenticated-orcid":false,"given":"James P. B.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-4961","authenticated-orcid":false,"given":"Luigi","family":"Aloj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-214X","authenticated-orcid":false,"given":"Anna","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-1590","authenticated-orcid":false,"given":"Phil J.","family":"Blower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3883-6287","authenticated-orcid":false,"given":"Kevin M.","family":"Brindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3795-5031","authenticated-orcid":false,"given":"Craig","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-746X","authenticated-orcid":false,"given":"Daniel","family":"Darian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2321-8091","authenticated-orcid":false,"given":"Vicky","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-3407","authenticated-orcid":false,"given":"David","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt G.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0973-0302","authenticated-orcid":false,"given":"Thomas A.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine D. G.","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-3234","authenticated-orcid":false,"given":"Penny L. Hubbard","family":"Cristinacce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowland O.","family":"Illing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-6567","authenticated-orcid":false,"given":"Baptiste","family":"Leurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0596-8200","authenticated-orcid":false,"given":"Sue","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-4390","authenticated-orcid":false,"given":"Radhouene","family":"Neji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6611-118X","authenticated-orcid":false,"given":"Natalia","family":"Norori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0843-2468","authenticated-orcid":false,"given":"Nora","family":"Pashayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-6340","authenticated-orcid":false,"given":"Neel","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-5480","authenticated-orcid":false,"given":"Thomas","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3712-0965","authenticated-orcid":false,"given":"Adam","family":"Retter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-4297","authenticated-orcid":false,"given":"Alasdair","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-1434","authenticated-orcid":false,"given":"Jasper","family":"van der Aart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Woollcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5214-3263","authenticated-orcid":false,"given":"Wai-Lup","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-2335","authenticated-orcid":false,"given":"Jan","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-0870","authenticated-orcid":false,"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-909X","authenticated-orcid":false,"given":"Geoff S.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"3831_CR1","doi-asserted-by":"publisher","first-page":"100455","DOI":"10.1016\/j.ejro.2022.100455","volume":"9","author":"E Franquet","year":"2022","unstructured":"Franquet E, Park H. Molecular imaging in oncology: Common PET\/CT radiopharmaceuticals and applications. Eur J Radiol Open. 2022;9: 100455.","journal-title":"Eur J Radiol Open"},{"issue":"2","key":"3831_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"3831_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-65768-0_1","volume":"1311","author":"S Bose","year":"2021","unstructured":"Bose S, Zhang C, Le A. Glucose Metabolism in Cancer: The Warburg Effect and Beyond. Adv Exp Med Biol. 2021;1311:3\u201315.","journal-title":"Adv Exp Med Biol"},{"key":"3831_CR4","doi-asserted-by":"publisher","first-page":"109168","DOI":"10.1016\/j.biopha.2019.109168","volume":"117","author":"WT Rahman","year":"2019","unstructured":"Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD, et al. The impact of infection and inflammation in oncologic (18)F-FDG PET\/CT imaging. Biomed Pharmacother. 2019;117: 109168.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"3831_CR5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2967\/jnumed.119.237446","volume":"61","author":"JR Barrio","year":"2020","unstructured":"Barrio JR, Huang SC, Satyamurthy N, Scafoglio CS, Yu AS, Alavi A, et al. Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization? J Nucl Med. 2020;61(6):931\u20137.","journal-title":"J Nucl Med"},{"issue":"12","key":"3831_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/RLU.0000000000001877","volume":"42","author":"J Kunikowska","year":"2017","unstructured":"Kunikowska J, Lewington V, Krolicki L. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT\/SPECT\/CT Versus 68Ga-DOTATATE PET\/CT Upon Clinical Management. Clin Nucl Med. 2017;42(12):905\u201311.","journal-title":"Clin Nucl Med"},{"key":"3831_CR7","doi-asserted-by":"publisher","first-page":"823667","DOI":"10.3389\/fonc.2022.823667","volume":"12","author":"AC Roden","year":"2022","unstructured":"Roden AC, Rakshit S, Johnson GB, Jenkins SM, Mansfield AS. Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors. Front Oncol. 2022;12: 823667.","journal-title":"Front Oncol"},{"issue":"2","key":"3831_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48(2):469\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3831_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.37894","volume":"10","author":"RA Werner","year":"2020","unstructured":"Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, et al. (18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. 2020;10(1):1\u201316.","journal-title":"Theranostics"},{"issue":"1","key":"3831_CR10","doi-asserted-by":"publisher","first-page":"e194003","DOI":"10.1148\/rycan.2019194003","volume":"1","author":"DK Hathi","year":"2019","unstructured":"Hathi DK, Jones EF. (68)Ga FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. Radiol Imaging Cancer. 2019;1(1): e194003.","journal-title":"Radiol Imaging Cancer"},{"issue":"8","key":"3831_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2967\/jnumed.123.265471","volume":"64","author":"G Wass","year":"2023","unstructured":"Wass G, Clifford K, Subramaniam RM. Evaluation of the Diagnostic Accuracy of FAPI PET\/CT in Oncologic Studies: Systematic Review and Metaanalysis. J Nucl Med. 2023;64(8):1218\u201324.","journal-title":"J Nucl Med"},{"issue":"2","key":"3831_CR12","doi-asserted-by":"publisher","first-page":"e220749","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease. Radiology. 2023;306(2): e220749.","journal-title":"Radiology"},{"key":"3831_CR13","doi-asserted-by":"publisher","first-page":"603837","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z Wei","year":"2020","unstructured":"Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of Amino Acids in Cancer. Front Cell Dev Biol. 2020;8: 603837.","journal-title":"Front Cell Dev Biol"},{"issue":"45","key":"3831_CR14","doi-asserted-by":"publisher","first-page":"e23060","DOI":"10.1097\/MD.0000000000023060","volume":"99","author":"B Emsen","year":"2020","unstructured":"Emsen B, Villafane G, David JP, Evangelista E, Chalaye J, Lerman L, et al. Clinical impact of dual-tracer FDOPA and FDG PET\/CT for the evaluation of patients with parkinsonian syndromes. Medicine (Baltimore). 2020;99(45): e23060.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3831_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00259-008-0989-5","volume":"36","author":"SA Eshuis","year":"2009","unstructured":"Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson\u2019s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36(3):454\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"3831_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/02698811221122031","volume":"36","author":"I Angelescu","year":"2022","unstructured":"Angelescu I, Kaar SJ, Marques TR, Borgan F, Veronesse M, Sharman A, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [(18)F]-FDOPA imaging in schizophrenia. J Psychopharmacol. 2022;36(9):1061\u20139.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"3831_CR17","first-page":"904","volume":"47","author":"W Chen","year":"2006","unstructured":"Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47(6):904\u201311.","journal-title":"J Nucl Med"},{"issue":"3","key":"3831_CR18","doi-asserted-by":"publisher","first-page":"e062555","DOI":"10.1136\/bmjopen-2022-062555","volume":"13","author":"T Xiaoxue","year":"2023","unstructured":"Xiaoxue T, Yinzhong W, Meng Q, Lu X, Lei J. Diagnostic value of PET with different radiotracers and MRI for recurrent glioma: a Bayesian network meta-analysis. BMJ Open. 2023;13(3): e062555.","journal-title":"BMJ Open"},{"issue":"3","key":"3831_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11060-022-04177-3","volume":"160","author":"JR Roach","year":"2022","unstructured":"Roach JR, Plaha P, McGowan DR, Higgins GS. The role of [(18)F]fluorodopa positron emission tomography in grading of gliomas. J Neurooncol. 2022;160(3):577\u201389.","journal-title":"J Neurooncol"},{"issue":"9","key":"3831_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","volume":"18","author":"NL Albert","year":"2016","unstructured":"Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199\u2013208.","journal-title":"Neuro Oncol"},{"issue":"3","key":"3831_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540\u201357.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"3831_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40644-020-00348-5","volume":"20","author":"F Somme","year":"2020","unstructured":"Somme F, Bender L, Namer IJ, Noel G, Bund C. Usefulness of (18)F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. Cancer Imaging. 2020;20(1):70.","journal-title":"Cancer Imaging"},{"issue":"1","key":"3831_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-019-5938-0","volume":"19","author":"J Xiao","year":"2019","unstructured":"Xiao J, Jin Y, Nie J, Chen F, Ma X. Diagnostic and grading accuracy of (18)F-FDOPA PET and PET\/CT in patients with gliomas: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):767.","journal-title":"BMC Cancer"},{"issue":"7","key":"3831_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/MNM.0000000000001030","volume":"40","author":"A Afaq","year":"2019","unstructured":"Afaq A, Gleeson F, Scarsbrook A, Bradley K, Subesinghe M, Macpherson R, et al. UK guidelines on 18F-fluciclovine PET\/CT in prostate cancer imaging. Nucl Med Commun. 2019;40(7):662\u201374.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"3831_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00259-019-04433-1","volume":"47","author":"L Michaud","year":"2020","unstructured":"Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, et al. (18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2020;47(6):1353\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3831_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13550-022-00876-0","volume":"12","author":"V Morath","year":"2022","unstructured":"Morath V, Heider M, Mittelhauser M, Rolbieski H, Stroh J, Calais J, et al. Initial evaluation of [(18)F]-FACBC for PET imaging of multiple myeloma. EJNMMI Res. 2022;12(1):4.","journal-title":"EJNMMI Res"},{"issue":"12","key":"3831_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1097\/RLU.0000000000004435","volume":"47","author":"SK Oen","year":"2022","unstructured":"Oen SK, Johannessen K, Pedersen LK, Berntsen EM, Totland JA, Johansen H, et al. Diagnostic Value of 18 F-FACBC PET\/MRI in Brain Metastases. Clin Nucl Med. 2022;47(12):1030\u20139.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"3831_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/jmri.25161","volume":"44","author":"H Sotoudeh","year":"2016","unstructured":"Sotoudeh H, Sharma A, Fowler KJ, McConathy J, Dehdashti F. Clinical application of PET\/MRI in oncology. J Magn Reson Imaging. 2016;44(2):265\u201376.","journal-title":"J Magn Reson Imaging"},{"issue":"6","key":"3831_CR29","doi-asserted-by":"publisher","first-page":"06RM1","DOI":"10.1088\/1361-6560\/abd4f7","volume":"66","author":"SR Meikle","year":"2021","unstructured":"Meikle SR, Sossi V, Roncali E, Cherry SR, Banati R, Mankoff D, et al. Quantitative PET in the 2020s: a roadmap. Phys Med Biol. 2021;66(6):06RM1.","journal-title":"Phys Med Biol."},{"issue":"11","key":"3831_CR30","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1007\/s00259-022-05824-7","volume":"49","author":"A Mehranian","year":"2022","unstructured":"Mehranian A, Wollenweber SD, Walker MD, Bradley KM, Fielding PA, Huellner M, et al. Deep learning-based time-of-flight (ToF) image enhancement of non-ToF PET scans. Eur J Nucl Med Mol Imaging. 2022;49(11):3740\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"3831_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","volume":"14","author":"JP O'Connor","year":"2017","unstructured":"O\u2019Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017;14(3):169\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3831_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2967\/jnumed.119.231308","volume":"61","author":"W McDougald","year":"2020","unstructured":"McDougald W, Vanhove C, Lehnert A, Lewellen B, Wright J, Mingarelli M, et al. Standardization of Preclinical PET\/CT Imaging to Improve Quantitative Accuracy, Precision, and Reproducibility: A Multicenter Study. J Nucl Med. 2020;61(3):461\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"3831_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40658-022-00503-w","volume":"9","author":"WA McDougald","year":"2022","unstructured":"McDougald WA, Mannheim JG. Understanding the importance of quality control and quality assurance in preclinical PET\/CT imaging. EJNMMI Phys. 2022;9(1):77.","journal-title":"EJNMMI Phys"},{"issue":"6","key":"3831_CR34","first-page":"1059","volume":"47","author":"LK Shankar","year":"2006","unstructured":"Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47(6):1059\u201366.","journal-title":"J Nucl Med"},{"issue":"12","key":"3831_CR35","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2967\/jnumed.120.244780","volume":"61","author":"DL Chen","year":"2020","unstructured":"Chen DL, Ballout S, Chen L, Cheriyan J, Choudhury G, Denis-Bacelar AM, et al. Consensus Recommendations on the Use of (18)F-FDG PET\/CT in Lung Disease. J Nucl Med. 2020;61(12):1701\u20137.","journal-title":"J Nucl Med"},{"key":"3831_CR36","doi-asserted-by":"crossref","unstructured":"The European Society of Radiology (ESR). ESR Statement on the Validation of Imaging Biomarkers. Insights into Imaging. 2020;11(1):76.","DOI":"10.1186\/s13244-020-00872-9"},{"issue":"1150","key":"3831_CR37","doi-asserted-by":"publisher","first-page":"20211126","DOI":"10.1259\/bjr.20211126","volume":"96","author":"PS Murphy","year":"2023","unstructured":"Murphy PS, Galette P, van der Aart J, Janiczek RL, Patel N, Brown AP. The role of clinical imaging in oncology drug development: progress and new challenges. Br J Radiol. 2023;96(1150):20211126.","journal-title":"Br J Radiol"},{"issue":"12","key":"3831_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/MNM.0000000000001461","volume":"42","author":"JD Young","year":"2021","unstructured":"Young JD, Jauregui-Osoro M, Wong WL, Cooper MS, Cook G, Barrington SF, et al. An overview of nuclear medicine research in the UK and the landscape for clinical adoption. Nucl Med Commun. 2021;42(12):1301\u201312.","journal-title":"Nucl Med Commun"},{"key":"3831_CR39","unstructured":"British Nuclear Medicine Society PET-CT Commissioning Manifesto Working Group. PET-CT Tracer Commissioning Manifesto. https:\/\/www.bnms.org.uk\/news\/657766\/BNMS-PET-CT-Commissioning-Manifesto.htm September 2023."},{"issue":"11","key":"3831_CR40","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41416-021-01497-5","volume":"125","author":"MA McAteer","year":"2021","unstructured":"McAteer MA, O\u2019Connor JPB, Koh DM, Leung HY, Doran SJ, Jauregui-Osoro M, et al. Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers. Br J Cancer. 2021;125(11):1462\u20135.","journal-title":"Br J Cancer"},{"key":"3831_CR41","unstructured":"Winona State University Library. Evidence-Based Practice Toolkit 2018 [Available from: https:\/\/libguides.winona.edu\/ebptoolkit\/Levels-Evidence#s-lg-box-179330."},{"key":"3831_CR42","unstructured":"Fitch K, Steven J. Bernstein, Maria Dolores Aguilar, Bernard Burnand, Juan Ramon LaCalle, Pablo Lazaro, Mirjam van het Loo, Joseph McDonnell, Janneke Vader, and James P. Kahan. The RAND\/UCLA Appropriateness Method User's Manual. 2001."},{"key":"3831_CR43","unstructured":"NCITA Exemplar Projects [Available from: https:\/\/ncita.org.uk\/ncita-exemplar-projects\/."},{"key":"3831_CR44","unstructured":"Fitch K. The Rand\/UCLA appropriateness method user's manual. Santa Monica: Rand; 2001. xiii, 109 p. p."},{"issue":"1","key":"3831_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bju.14361","volume":"122","author":"M Brizmohun Appayya","year":"2018","unstructured":"Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, et al. National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. BJU Int. 2018;122(1):13\u201325.","journal-title":"BJU Int"},{"issue":"1081","key":"3831_CR46","doi-asserted-by":"publisher","first-page":"20170577","DOI":"10.1259\/bjr.20170577","volume":"91","author":"A Barnes","year":"2018","unstructured":"Barnes A, Alonzi R, Blackledge M, Charles-Edwards G, Collins DJ, Cook G, et al. UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. Br J Radiol. 2018;91(1081):20170577.","journal-title":"Br J Radiol"},{"issue":"1","key":"3831_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13014-019-1343-8","volume":"14","author":"ER Biglin","year":"2019","unstructured":"Biglin ER, Price GJ, Chadwick AL, Aitkenhead AH, Williams KJ, Kirkby KJ. Preclinical dosimetry: exploring the use of small animal phantoms. Radiat Oncol. 2019;14(1):134.","journal-title":"Radiat Oncol"},{"issue":"1","key":"3831_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40658-021-00408-0","volume":"8","author":"E Lennie","year":"2021","unstructured":"Lennie E, Tsoumpas C, Sourbron S. Multimodal phantoms for clinical PET\/MRI. EJNMMI Phys. 2021;8(1):62.","journal-title":"EJNMMI Phys"},{"key":"3831_CR49","unstructured":"Broad Institute CCLE Cancer Cell Line Encyclopedia [Available from: https:\/\/sites.broadinstitute.org\/ccle\/."},{"key":"3831_CR50","unstructured":"The Human Protein Atlas [Available from: https:\/\/www.proteinatlas.org\/."},{"key":"3831_CR51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3389\/fnins.2020.00871","volume":"14","author":"RC Shaw","year":"2020","unstructured":"Shaw RC, Tamagnan GD, Tavares AAS. Rapidly (and Successfully) Translating Novel Brain Radiotracers From Animal Research Into Clinical Use. Front Neurosci. 2020;14:871.","journal-title":"Front Neurosci"},{"issue":"1","key":"3831_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41181-022-00168-x","volume":"7","author":"A Korde","year":"2022","unstructured":"Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, et al. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2022;7(1):18.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"3831_CR53","unstructured":"Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes Text with EEA relevance [Available from: https:\/\/eur-lex.europa.eu\/eli\/dir\/2010\/63\/oj."},{"issue":"1","key":"3831_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2967\/jnumed.116.184028","volume":"59","author":"SR Cherry","year":"2018","unstructured":"Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. J Nucl Med. 2018;59(1):3\u201312.","journal-title":"J Nucl Med"},{"issue":"1","key":"3831_CR55","doi-asserted-by":"publisher","first-page":"15985","DOI":"10.1038\/s41598-020-72830-w","volume":"10","author":"AA Garrow","year":"2020","unstructured":"Garrow AA, Andrews JPM, Gonzalez ZN, Corral CA, Portal C, Morgan TEF, et al. Preclinical dosimetry models and the prediction of clinical doses of novel positron emission tomography radiotracers. Sci Rep. 2020;10(1):15985.","journal-title":"Sci Rep"},{"issue":"1","key":"3831_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ilar.49.1.17","volume":"49","author":"IJ Hildebrandt","year":"2008","unstructured":"Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J. 2008;49(1):17\u201326.","journal-title":"ILAR J"},{"key":"3831_CR57","doi-asserted-by":"crossref","unstructured":"Lau J, Rousseau E, Kwon D, Lin KS, Benard F, Chen X. Insight into the Development of PET Radiopharmaceuticals for Oncology. Cancers (Basel). 2020;12(5):1312.","DOI":"10.3390\/cancers12051312"},{"issue":"6","key":"3831_CR58","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932\u201345.","journal-title":"J Nucl Med"},{"key":"3831_CR59","doi-asserted-by":"crossref","unstructured":"Adashi EY, O'Mahony DP, Cohen IG. The FDA Modernization Act 2.0: Drug Testing in Animals is Rendered Optional. Am J Med. 2023;136(9):853\u20134.","DOI":"10.1016\/j.amjmed.2023.03.033"},{"issue":"3","key":"3831_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/aor.14503","volume":"47","author":"JJ Han","year":"2023","unstructured":"Han JJ. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif Organs. 2023;47(3):449\u201350.","journal-title":"Artif Organs."},{"issue":"8","key":"3831_CR61","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41551-023-01154-7","volume":"8","author":"DM Stresser","year":"2024","unstructured":"Stresser DM, Kopec AK, Hewitt P, Hardwick RN, Van Vleet TR, Mahalingaiah PKS, et al. Towards in vitro models for reducing or replacing the use of animals in drug testing. Nat Biomed Eng. 2024;8(8):930\u20135.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"3831_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCULATIONAHA.123.065585","volume":"148","author":"SM Ahmed","year":"2023","unstructured":"Ahmed SM, Shivnaraine RV, Wu JC. FDA Modernization Act 2.0 Paves the Way to Computational Biology and Clinical Trials in a Dish. Circulation. 2023;148(4):309\u201311.","journal-title":"Circulation."},{"key":"3831_CR63","doi-asserted-by":"crossref","unstructured":"Loffler J, Herrmann H, Scheidhauer E, Wirth M, Wasserloos A, Solbach C, et al. Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging. Cancers (Basel). 2022;14(16):3870.","DOI":"10.3390\/cancers14163870"},{"key":"3831_CR64","doi-asserted-by":"crossref","unstructured":"Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and Prospects of Patient-Derived Xenografts for Cancer Research. Cancers (Basel). 2023;15(17):4352.","DOI":"10.3390\/cancers15174352"},{"issue":"1","key":"3831_CR65","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):160.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"3831_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/pharmaceutics4030442","volume":"4","author":"SL Barnes","year":"2012","unstructured":"Barnes SL, Whisenant JG, Loveless ME, Yankeelov TE. Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics. 2012;4(3):442\u201378.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3831_CR67","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s00259-009-1347-y","volume":"37","author":"E Busemann Sokole","year":"2010","unstructured":"Busemann Sokole E, Plachcinska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging. 2010;37(3):662\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"3831_CR68","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/jmri.24955","volume":"42","author":"S Doblas","year":"2015","unstructured":"Doblas S, Almeida GS, Ble FX, Garteiser P, Hoff BA, McIntyre DJ, et al. Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study. J Magn Reson Imaging. 2015;42(6):1759\u201364.","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"3831_CR69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/tomography9010030","volume":"9","author":"D Malyarenko","year":"2023","unstructured":"Malyarenko D, Amouzandeh G, Pickup S, Zhou R, Manning HC, Gammon ST, et al. Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom. Tomography. 2023;9(1):375\u201386.","journal-title":"Tomography"},{"key":"3831_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mri.2019.03.008","volume":"59","author":"JC Waterton","year":"2019","unstructured":"Waterton JC, Hines CDG, Hockings PD, Laitinen I, Ziemian S, Campbell S, et al. Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systems. Magn Reson Imaging. 2019;59:121\u20139.","journal-title":"Magn Reson Imaging"},{"issue":"6","key":"3831_CR71","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1111\/hex.13615","volume":"25","author":"P Carroll","year":"2022","unstructured":"Carroll P, Dervan A, Maher A, McCarthy C, Woods I, Kavanagh R, et al. Applying Patient and Public Involvement in preclinical research: A co-created scoping review. Health Expect. 2022;25(6):2680\u201399.","journal-title":"Health Expect"},{"issue":"5","key":"3831_CR72","doi-asserted-by":"publisher","first-page":"e0216600","DOI":"10.1371\/journal.pone.0216600","volume":"14","author":"J Maccarthy","year":"2019","unstructured":"Maccarthy J, Guerin S, Wilson AG, Dorris ER. Facilitating public and patient involvement in basic and preclinical health research. PLoS ONE. 2019;14(5): e0216600.","journal-title":"PLoS ONE"},{"key":"3831_CR73","unstructured":"Cancer Research UK. Patient involvement toolkit for researchers [Available from: https:\/\/www.cancerresearchuk.org\/funding-for-researchers\/patient-involvement-toolkit-for-researchers."},{"key":"3831_CR74","unstructured":"NIHR UK Standards for Public Involvement. [Available from: https:\/\/sites.google.com\/nihr.ac.uk\/pi-standards\/home."},{"key":"3831_CR75","unstructured":"UK Research and Innovation. How we support public engagement [Available from: https:\/\/www.ukri.org\/what-we-offer\/public-engagement\/how-we-support-public-engagement\/."},{"issue":"2","key":"3831_CR76","doi-asserted-by":"publisher","first-page":"103800","DOI":"10.1016\/j.isci.2022.103800","volume":"25","author":"C Pfander","year":"2022","unstructured":"Pfander C, Bischof J, Childress-Poli M, Keppler A, Viale A, Aime S, et al. Euro-BioImaging - Interdisciplinary research infrastructure bringing together communities and imaging facilities to support excellent research. iScience. 2022;25(2):103800.","journal-title":"iScience."},{"issue":"5","key":"3831_CR77","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00259-004-1495-z","volume":"31","author":"H Zaidi","year":"2004","unstructured":"Zaidi H, Koral KF. Scatter modelling and compensation in emission tomography. Eur J Nucl Med Mol Imaging. 2004;31(5):761\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"3831_CR78","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41591-023-02490-6","volume":"29","author":"F Bompart","year":"2023","unstructured":"Bompart F, Fisher JA, Allen E, Sevene E, Kumar N, Chew CK, et al. The VolREthics initiative to protect the well-being of healthy volunteers in biomedical research. Nat Med. 2023;29(10):2393\u20134.","journal-title":"Nat Med"},{"key":"3831_CR79","unstructured":"Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources 2023 [Available from: https:\/\/www.gov.uk\/government\/publications\/arsac-notes-for-guidance."},{"issue":"1","key":"3831_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MNM.0000000000001779","volume":"45","author":"GJR Cook","year":"2024","unstructured":"Cook GJR, Dickson J, Chicklore S, Dempsey M, Ferreira A, MacKewn J, et al. BNMS UK PET standards. Nucl Med Commun. 2024;45(1):1\u201315.","journal-title":"Nucl Med Commun"},{"key":"3831_CR81","unstructured":"European Association of Nuclear Medicine (EANM) guidelines for oncology [Available from: https:\/\/www.eanm.org\/publications\/guidelines\/oncology\/."},{"key":"3831_CR82","unstructured":"Developing NICE guidelines: the manual [Available from: https:\/\/www.nice.org.uk\/process\/pmg20\/resources\/developing-nice-guidelines-the-manual-pdf-72286708700869."},{"issue":"14","key":"3831_CR83","doi-asserted-by":"publisher","first-page":"15530","DOI":"10.1002\/cam4.6200","volume":"12","author":"S Colomer-Lahiguera","year":"2023","unstructured":"Colomer-Lahiguera S, Steimer M, Ellis U, Eicher M, Tompson M, Corbiere T, et al. Patient and public involvement in cancer research: A scoping review. Cancer Med. 2023;12(14):15530\u201343.","journal-title":"Cancer Med"},{"issue":"1","key":"3831_CR84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hex.12841","volume":"22","author":"KH Pii","year":"2019","unstructured":"Pii KH, Schou LH, Piil K, Jarden M. Current trends in patient and public involvement in cancer research: A systematic review. Health Expect. 2019;22(1):3\u201320.","journal-title":"Health Expect"},{"key":"3831_CR85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40900-017-0062-2","volume":"3","author":"S Staniszewska","year":"2017","unstructured":"Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. Res Involv Engagem. 2017;3:13.","journal-title":"Res Involv Engagem"},{"key":"3831_CR86","unstructured":"EIBALL European Imaging Biomarkers Alliance [Available from: https:\/\/www.myesr.org\/research\/eiball\/."},{"key":"3831_CR87","unstructured":"RSNA Quantitative Imaging Biomarkers Alliance (QIBA) [Available from: https:\/\/www.rsna.org\/news\/2021\/april\/qiba-a-quantitative-success."},{"key":"3831_CR88","unstructured":"The National Cancer Institute Cancer Imaging Archive (TCIA) [Available from: https:\/\/www.cancerimagingarchive.net\/."},{"issue":"1","key":"3831_CR89","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S1470-2045(23)00511-9","volume":"25","author":"A Aggarwal","year":"2024","unstructured":"Aggarwal A, Choudhury A, Fearnhead N, Kearns P, Kirby A, Lawler M, et al. The future of cancer care in the UK-time for a radical and sustainable National Cancer Plan. Lancet Oncol. 2024;25(1):e6\u201317.","journal-title":"Lancet Oncol"},{"key":"3831_CR90","doi-asserted-by":"crossref","unstructured":"The Lancet, Oncology. Still waiting for a UK cancer plan that truly delivers. Lancet Oncol. 2022;23(12):1475.","DOI":"10.1016\/S1470-2045(22)00702-1"},{"key":"3831_CR91","unstructured":"The Society of Radiographers. Diagnostic radiography workforce UK census 2021 [Available from: https:\/\/www.sor.org\/learning-advice\/professional-body-guidance-and-publications\/documents-and-publications\/reports-and-surveys\/cor-diagnostic-radiography-workforce-census-2021."},{"issue":"4","key":"3831_CR92","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","volume":"22","author":"H Hricak","year":"2021","unstructured":"Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, et al. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol. 2021;22(4):e136\u201372.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3831_CR93","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.radi.2024.01.001","volume":"30","author":"E Susiku","year":"2024","unstructured":"Susiku E, Hewitt-Taylor J, Akudjedu TN. Graduate competencies, employability and the transnational Radiography workforce shortage: A systematic literature review of current pre-registration Radiography education and training models. Radiography (Lond). 2024;30(2):457\u201367.","journal-title":"Radiography (Lond)"},{"issue":"3","key":"3831_CR94","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jmir.2015.06.011","volume":"46","author":"M Griffiths","year":"2015","unstructured":"Griffiths M. Creating the Hybrid Workforce: Challenges and Opportunities. J Med Imaging Radiat Sci. 2015;46(3):262\u201370.","journal-title":"J Med Imaging Radiat Sci"},{"key":"3831_CR95","unstructured":"PET-CT scanning competencies for clinical scientists & for clinical technologists\/radiographers 2006 [Available from: https:\/\/cdn.ymaws.com\/www.bnms.org.uk\/resource\/resmgr\/schools_&_students\/06_04_-_pet-ct_training_requ.pdf."},{"issue":"1","key":"3831_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41824-019-0070-6","volume":"4","author":"MO Mada","year":"2020","unstructured":"Mada MO, Hindmarch P, Stirling J, Davies J, Brian D, Barnes A, et al. Competencies and training of radiographers and technologists for PET\/MR imaging - a study from the UK MR-PET network. Eur J Hybrid Imaging. 2020;4(1):1.","journal-title":"Eur J Hybrid Imaging"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03831-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03831-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03831-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:16:21Z","timestamp":1737630981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03831-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3831"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03831-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB and DD are employees of and hold shares in Siemens Healthineers. At the time of the consensus meeting, RN was an employee of Siemens Healthineers, and holds shares from Siemens Healthineers. PE is an employee of GE Healthcare. CDGH and JvdA are employees of and own stocks in GSK. TN is an employee of GSK.\u00a0SJH is a fulltime employee of AstraZeneca, and receives salary, and receives and holds shares; and is a member of the UKRI Medical Research Council (MRC) Council. NN and JW are employees of Prostate Cancer UK. NP is an employee of Telix Pharmaceuticals Ltd. TR is an employee and shareholder of Evergreen Theragnostics, Inc. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}